{
  "nctId": "NCT02375867",
  "briefTitle": "Steroids in Fulminant Hepatitis A in the Pediatric Age Group",
  "officialTitle": "Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group",
  "protocolDocument": {
    "nctId": "NCT02375867",
    "filename": "Prot_SAP_001.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2018-12-11",
    "uploadDate": "2018-12-11T04:10",
    "size": 2688869,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02375867/document/Prot_SAP_001.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE4"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "FACTORIAL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 33,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2015-01",
    "completionDate": "2017-09",
    "primaryCompletionDate": "2017-08",
    "firstSubmitDate": "2015-02-14",
    "firstPostDate": "2015-03-03"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\nThe patient is diagnosed to have FHF, if he fulfilled all the following criteria:\n\n1. Evidence of liver dysfunction within 8 weeks of onset of symptoms (neonates may have only deranged liver functions without overt symptoms).\n2. Uncorrectable coagulopathy (6-8 hours after administration of one dose of parenteral vitamin K) with International Normalized Ratio (INR) \\>1.5 in patients with hepatic encephalopathy, or INR\\> 2.0 in patients without encephalopathy.\n3. No evidence of chronic liver disease.\n\nExclusion Criteria:\n\n1\\. Presence of absolute contra-indications to steroid therapy (as presence of an active gastrointestinal bleeding, renal failure, acute pancreatitis, active tuberculosis, uncontrolled diabetes and psychosis).",
    "healthyVolunteers": false,
    "sex": "ALL",
    "maximumAge": "18 Years",
    "stdAges": [
      "CHILD",
      "ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Side effect 1 Number of patients with anaphylaxis",
        "description": "Number of patients with anaphylaxis",
        "timeFrame": "2 months"
      },
      {
        "measure": "Side effect 2 Number of patients with angioedema",
        "description": "Number of patients with angioedema",
        "timeFrame": "2 months"
      },
      {
        "measure": "Side effect 3 Number of patients with cardiac arrest",
        "description": "Number of patients with cardiac arrest",
        "timeFrame": "2 months"
      },
      {
        "measure": "Side effect 4 Number of patients with arrhythmias",
        "description": "Number of patients with arrhythmias",
        "timeFrame": "2 months"
      },
      {
        "measure": "Side effect 5 Number of patients with circulatory collapse",
        "description": "Number of patients with circulatory collapse",
        "timeFrame": "2 months"
      },
      {
        "measure": "Side effect 6 Number of patients with congestive heart failure",
        "description": "Number of patients with congestive heart failure",
        "timeFrame": "2 months"
      },
      {
        "measure": "Side effect 7 Number of patients with pulmonary edema",
        "description": "Number of patients with pulmonary edema",
        "timeFrame": "2 months"
      },
      {
        "measure": "Side effect 8 Number of patients with pancreatitis",
        "description": "Number of patients with pancreatitis",
        "timeFrame": "2 months"
      }
    ],
    "secondary": [
      {
        "measure": "Efficacy 1 Number of survivors",
        "description": "number of living patients",
        "timeFrame": "2 months"
      },
      {
        "measure": "Efficacy 2 Number of deaths",
        "description": "number of died patients",
        "timeFrame": "2 months"
      },
      {
        "measure": "Efficacy 3 serum prothrombin time",
        "description": "serum prothrombin time",
        "timeFrame": "72 hour"
      },
      {
        "measure": "Efficacy 3 grade of encephalopathy",
        "description": "grade of encephalopathy",
        "timeFrame": "72 hour"
      },
      {
        "measure": "Efficacy 4 duration of encephalopathy",
        "description": "duration of encephalopathy",
        "timeFrame": "2 months"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 8,
      "secondaryCount": 5,
      "otherCount": 0,
      "totalCount": 13
    },
    "studyDesign": {
      "phases": [
        "PHASE4"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "FACTORIAL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:25.036Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}